Geron Corp GERN

Alternate Symbol(s): GERNW

Healthcare Biotechnology

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

NDAQ:GERN - Post by User

Geron Corp

Bullboard Posts

Post by vforvalueon May 23, 2008 2:28pm

695 Views

Post# 15104658

Justified?

https://www.stockhouse.com/Columnists/2008/May/15/Stem-cells-may-boost-biotech-company

This article explains GERN's long history of its ups and downs. It also comments on its current position in the market.

This company has alot of cash and no debt in its books. This gives this company a chance to pick itself up from the ground and go up.

However,it really needs to focus on beating its competitors. Although it hasreported a 85% quarterly revenue growth, its competitors are reporting200-600% growth. Hence, this company needs to find a successfulcompetitive advantage.

Other than that, it is up for the politics to determine the general trend for all bio companies.

Bullboard Posts

MDA Space stock blasts off on Q3 financial results